HemaQuest Pharmaceuticals   Report issue

For profit Phase 2
Founded: Seattle WA United States (2007)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2008
NCT00614016
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

HemaQuest Pharmaceuticals Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

beta-Thalassemia (Phase 2)

Disease (Phase 2)

Lymphoproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Sickle Cell Trait (Phase 2)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 4